Retatrutide resets expectations for weight-loss efficacy, while the Eloralintide development program expands significantly

Overview

This report reviews Eli Lilly's cardiometabolic investor event at ADA 2026, the Retatrutide TRIUMPH-1 obesity trial, the TRANSCEND-T2D-1 diabetes trial, and the Eloralintide development program. Bernstein believes Retatrutide's depth of weight loss, low-dose tolerability, and broad applicability materially improve Lilly's portfolio quality in obesity and metabolic diseases; Eloralintide, as a non-incretin selective Amylin-1 agonist, could also become an important next-generation asset for monotherapy or combination treatment.

Core views

The core view is that Retatrutide has raised the efficacy bar further in obesity treatment, with the 12mg dose approaching 30% weight loss, while the 4mg dose offers a better balance between efficacy and adverse events; in type 2 diabetes, Retatrutide's weight-loss differentiation is clearer, while glycemic control may be constrained by a normal-glycemia floor effect; Eloralintide's tolerability, no need for 3mg titration, and combination potential with tirzepatide could make it an important future expansion asset in Lilly's obesity pipeline.

Analysis framework

The report mainly draws on disclosures from the ADA meeting, Q&A from Lilly management's investor event, clinical data from TRIUMPH-1 and TRANSCEND-T2D-1, cross-trial comparisons, and commercialization pathway assessments to comprehensively evaluate efficacy, safety, regulatory progress, target populations, and portfolio positioning.

Methodology notes

• Clinical data interpretationPhase III trial readout assessment

  Balance between efficacy and tolerability

  The analysis focuses on comparing weight loss, HbA1c reduction, discontinuation rates, and gastrointestinal adverse events across different Retatrutide doses to assess its differentiation versus existing incretin drugs.

• Commercialization analysisPortfolio and channel expansion assessment

  Parallel insurance-pay and cash-pay channels

  Management said there is no reason to restrict Retatrutide's channels, leading the report to conclude that the product may serve not only the most severe, most clinically necessary insured patients, but also cash-pay or consumer segments.

• Pipeline assessmentMechanism differentiation analysis

  Amylin-1 selectivity and non-incretin option

  Eloralintide is positioned as a selective Amylin-1 agonist, potentially providing a monotherapy or combination-treatment path independent of GLP-1/GIP mechanisms, especially for patients needing better tolerability or additional weight loss.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• LLY.N

  Stock of the company covered by the report

  Strengths

  Owns a multi-layered obesity and diabetes portfolio including Retatrutide, Eloralintide, Orforglipron, and tirzepatide; ADA data reinforce the long-term leadership narrative.

  Weaknesses

  Valuation and long-term growth expectations are highly dependent on delivery from the obesity/metabolic disease pipeline, and key indications still require regulatory and long-term outcomes validation.

  Comparison

  Compared with a single GLP-1 or GIP/GLP-1 product, the company's portfolio spans injectable, oral, incretin, and non-incretin mechanisms.

  Risks

  High-dose adverse events, regulatory pathways, payor and channel strategy, competitive fast-follow products, and delayed long-term outcomes readouts.

• Retatrutide

  Core pipeline asset for obesity and type 2 diabetes

  Strengths

  TRIUMPH-1 showed 28.3%-30.3% weight loss, while the 4mg low dose combines strong efficacy with favorable discontinuation rates; weight loss is also significant in T2D.

  Weaknesses

  HbA1c improvement did not clearly exceed tirzepatide, and high-dose GI events, injection-site reactions, dysesthesia, and UTI signals require continued monitoring.

  Comparison

  The report believes its weight-loss performance is more differentiated than existing incretin therapies, but glycemic-control comparisons are affected by trial design and the normal-glycemia floor effect.

  Risks

  There remains regulatory uncertainty around obesity filing in H2 2026 and T2D filing in H1 2027, while outcomes data are not expected until Q1 2029.

• Eloralintide

  Next-generation obesity asset based on the Amylin mechanism

  Strengths

  Phase II monotherapy delivered 12.4%-16.4% weight loss, tolerability close to placebo, no need for 3mg titration, and potential use as monotherapy or add-on to incretins.

  Weaknesses

  Larger Phase III and combination-therapy data are still needed, and it remains unclear whether monotherapy can replace GLP-1 or will mainly serve as add-on therapy.

  Comparison

  Unlike GLP-1/GIP incretins, its non-incretin and Amylin-1 selectivity may provide mechanistic complementarity.

  Risks

  Phase III results, combination data with tirzepatide, target-population positioning, and long-term safety remain key uncertainties.

• Orforglipron / Foundayo

  Commercialized oral asset for obesity and T2D

  Strengths

  Approved in the U.S. in April 2026 for weight management, with strong early launch feedback; ACHIEVE-3 delivered a 2.2% HbA1c reduction and ATTAIN-1 delivered 12.4% weight loss.

  Weaknesses

  Broad rollout has not yet begun, and the pace of long-term volume ramp, demand from low-BMI patients, and international/T2D approvals still need to be observed.

  Comparison

  As a daily oral small-molecule GLP-1, it is positioned as a scalable foundational treatment option that complements injectable products.

  Risks

  International filings, U.S. T2D submission, upcoming ADA data, and competing oral technology pathways may affect market expectations.

Key data

• Bernstein ratingOutperformThe report explicitly states an Outperform rating on LLY.
• Price target1,300.00 USDThe report cover page discloses a Price Target of 1,300.00 USD.
• Retatrutide TRIUMPH-1 weight loss28.3%; extended subset 30.3%The 80-week data are close to bariatric-surgery-level outcomes.
• Retatrutide 4mg low-dose weight lossabout 17%-19%The report emphasizes that the 4mg dose had discontinuation due to adverse events no higher than placebo, making it attractive.
• TRIUMPH-1 BMI resultsMore than 1/3 reached normal BMI, about 2/3 were no longer obese, and 45% lost more than 30% of body weightWith a baseline average BMI of about 40, this demonstrates the clinical significance of deep weight loss.
• TRANSCEND-T2D-1 results16.8% weight loss, about 2% HbA1c reductionEfficacy may not yet have fully plateaued at 40 weeks.
• HbA1c target achievementUp to 85% achieved HbA1c ≤6.5%, and up to 46% approached normal glycemia <5.7%This suggests strong glycemic control, but no clear comprehensive superiority versus tirzepatide.
• Eloralintide Phase II monotherapy weight loss12.4%-16.4%The report says there is no evidence yet of an efficacy plateau, and gastrointestinal tolerability was close to placebo.
• Eloralintide Phase III plan5 Phase III studies ongoingIncluding OSA, OA knee pain, and add-on weight-loss studies in combination with incretins.
• Key upcoming timelinesRetatrutide obesity filing in H2 2026, T2D filing in H1 2027; Eloralintide+tirzepatide data in H2 2026; TRIUMPH-Outcomes expected in Q1 2029These timelines will affect regulatory progress, commercialization, and long-term outcomes validation.

Impact & implications

If confirmed in subsequent studies, Retatrutide could strengthen Lilly's leadership in the high-efficacy segment of obesity treatment and broaden coverage from early low-dose treatment to high-dose severe-obesity patients. Eloralintide provides a non-incretin mechanism and combination-therapy option, potentially enhancing Lilly's ability to address different patient subgroups, tolerability needs, and long-term treatment pathways.

Risks

• Gastrointestinal adverse events and discontinuation due to adverse events were higher in the high-dose Retatrutide group than in the low-dose group, requiring attention to dose selection and real-world tolerability.
• TRIUMPH-1 showed an imbalance in UTI incidence, mainly in women and mostly mild to moderate, with the mechanism still unclear.
• Injection-site reactions, dysesthesia, short-term heart-rate increases, and some adverse events of special interest still require confirmation in subsequent Phase III and long-term data.
• HbA1c improvement did not show a clear advantage versus tirzepatide, which may limit its differentiation narrative in the diabetes market.
• Regulatory pathways, including accelerated approval under CNPV, BMI 24-29 or consumer indications, and weight-maintenance indications, remain uncertain.
• Fast-follow and me-too competitors may shorten Lilly's early data advantage.

What to watch

• More ADA data on Orforglipron ACHIEVE-2, ACHIEVE-3, and ACHIEVE-5 on June 8, 2026.
• Progress of Retatrutide obesity indication filing in H2 2026.
• Progress of Retatrutide type 2 diabetes indication filing in H1 2027.
• Phase II combination data for Eloralintide with tirzepatide, expected in H2 2026.
• Progress of Eloralintide Phase III studies such as ENLIGHTEN-3, ENLIGHTEN-4, and ENLIGHTEN-5.
• Whether OSA and OA knee-pain basket studies and subsequent supplemental Phase III trials can support a broader registration package.
• The long-term outcomes study TRIUMPH-Outcomes, expected to read out in Q1 2029.
• Whether Retatrutide enters cash-pay, DTC, or broader consumer channels, and how it is deployed alongside Zepbound/Mounjaro.